Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
4,992,318
-
Total 13F shares
-
68,137,745
-
Share change
-
-265,069
-
Total reported value
-
$1,813,136,515
-
Put/Call ratio
-
39%
-
Price per share
-
$26.61
-
Number of holders
-
147
-
Value change
-
+$51,864,511
-
Number of buys
-
81
-
Number of sells
-
59
Institutional Holders of Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) as of Q4 2020
As of 31 Dec 2020,
Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) was held by
147 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
68,137,745 shares.
The largest 10 holders included
BlackRock Inc., Avoro Capital Advisors LLC, WELLINGTON MANAGEMENT GROUP LLP, Bain Capital Life Sciences Investors, LLC, PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, VANGUARD GROUP INC, Sarissa Capital Management LP, Rock Springs Capital Management LP, and CITADEL ADVISORS LLC.
This page lists
147
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.